본문 바로가기

Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
Annals of Laboratory Medicine35(3) · pp.288 · 2015
피인용
Web of Science 22KCI 1
JCR IF
JCR 2014 1.417
ISSN
2234-3806

저자

  1. 박상혁제1저자Pusan National University Hospital
  2. Hyun Ji LeeKorean Red cross
  3. 김인숙Pusan National University Yangsan Hospital
  4. Jeong-Eun KangJinhae Yonsei Hospital
  5. 이은엽Pusan National University Hospital
  6. Hyeoung-Joon KimChonnam National University Hwasun Hospital
  7. Yeo-Kyeoung KimChonnam National University Hwasun Hospital
  8. Jong-Ho WonSoonchunhyang University Hospital
  9. Soo-Mee BangSeoul National University Bundang Hospital
  10. Hawk KimUlsan University Hospital
  11. 송무곤Pusan National University Hospital
  12. 정주섭Pusan National University Hospital
  13. 신호진교신저자Pusan National University

초록

Background: To identify potential molecular prognostic markers in core binding factor (CBF) AML, we analyzed incidences and prognostic impacts of mutations in c-KIT, WT1, CEBPA, CBL, and a number of epigenetic genes in CBF AML. Methods: Seventy one and 21 AML patients with t(8;21) and inv(16) were enrolled in this study, respectively. NPM1, CEBPA, c-KIT, IDH1/2, DNMT3A, EZH2, WT1, and CBL mutations were analyzed by direct sequencing. Patients were categorized with respect to c-KIT and WT1 mutation status, and both clinical features and prognoses were compared. Results: The incidences of FLT3 internal tandem duplication (ITD), NPM1, CEBPA, IDH1/2, DNMT3A, EZH2, and CBL mutations were low (<= 5%) in CBF AML patients. However, c-KIT and WT1 mutations occurred frequently (10.9% and 13.8%, respectively). t(8;21) patients with c-KIT mutations showed significantly shorter overall survival (OS) and disease free survival (DFS) periods than those without mutations (P<0.001, for both); however, although the limited number of t(8;21) patients were analyzed, WT1 mutation status did not affect prognosis significantly. Relapse or death during follow-up occurred more frequently in t(8;21) patients carrying c-KIT mutations than in those without the mutation, although the difference was significant only in a specific patient subgroup with no WT1 mutations (P=0.014). Conclusions: The incidences of mutations in epigenetic genes are very low in CBF AML; however, c-KIT and WT1 mutations occur more frequently than others. The poor prognostic impact of c-KIT mutation in t(8;21) AML patients only applies in a specific patient subgroup without WT1 mutations. The prognostic impact of WT1 mutation in CBF AML is not evident and further investigation is required.

키워드

Acute myeloid leukemiaCore binding factorc-KITEpigenetic modificationIncidencePrognosisWT1RAS GENE-MUTATIONSDNMT3A MUTATIONSNORMAL KARYOTYPENUCLEOPHOSMIN 1FLT3EXPRESSIONNPM1DIAGNOSISAML

식별자

WoS UID
000352754600002
KCI
ART001982055